Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Conjuchem (TSE:CJC) said in an international Phase II trial in 206 Type II diabetes patients, DAC:GLP-1
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury